南华生物(000504) - 2024 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2024 was ¥25,973,854.69, a decrease of 25.23% compared to ¥34,739,572.68 in the same period last year[5] - The net loss attributable to shareholders was ¥2,770,653.53, representing a 40.21% increase from a loss of ¥1,976,045.11 in the previous year[5] - The company's basic and diluted earnings per share were both -¥0.0084, a decrease of 33.33% from -¥0.0063 in the same period last year[5] - Net loss for Q1 2024 was CNY -2,846,531.87, compared to a profit of CNY 437,868.11 in Q1 2023, indicating a significant decline in profitability[20] - Basic and diluted earnings per share for Q1 2024 were both CNY -0.0084, compared to CNY -0.0063 in the previous year[20] Cash Flow - The net cash flow from operating activities was -¥1,504,744.35, a significant decline of 779.35% from ¥221,498.68 in the same period last year[5] - Cash inflow from operating activities was CNY 40,257,981.62, down 27.8% from CNY 55,798,690.84 in Q1 2023[21] - The net cash flow from investment activities was -118,821,316.99, a substantial increase in losses compared to -9,858,235.23 in Q1 2023[23] - The net cash flow from financing activities was -160,857,327.41, worsening from -3,440,558.04 in Q1 2023[23] - The total cash and cash equivalents at the end of Q1 2024 stood at 212,597,686.65, compared to 205,040,966.14 at the end of Q1 2023[23] Assets and Liabilities - Total assets decreased by 20.75% to ¥611,302,774.92 from ¥771,382,516.09 at the end of the previous year[5] - The total liabilities decreased to CNY 309,475,438.53 from CNY 466,708,647.83 in the previous year, indicating improved financial stability[19] - The total equity attributable to shareholders of the parent company was CNY 254,170,544.84, a slight decrease from CNY 256,941,198.37 year-over-year[19] Operational Costs - Total operating costs for Q1 2024 were CNY 29,981,563.79, down 16.4% from CNY 35,814,358.27 year-over-year[19] - Research and development expenses for Q1 2024 were CNY 2,184,441.44, slightly down from CNY 2,197,527.49 in the same period last year[19] - Sales expenses decreased to CNY 7,414,026.52, a reduction of 15.2% compared to CNY 8,743,639.48 in Q1 2023[19] - Management expenses were CNY 10,585,520.54, down from CNY 11,823,853.16 year-over-year, reflecting a cost control strategy[19] Shareholder Information - The total number of common shareholders at the end of the reporting period is 15,387[11] - The company issued 18,449,197 shares in 2023, raising a total of approximately ¥276 million, with a net amount of ¥271 million after deducting issuance costs[12] - The company has no preferred shareholders or related party transactions among the top shareholders[12] Inventory and Current Assets - The company's inventory increased by 33.33% to ¥14,212,949.89 from ¥10,660,296.88, indicating a rise in engineering materials[8] - Other current assets surged by 224.43% to ¥23,453,184.31 from ¥7,229,117.81, attributed to increased bank wealth management purchases[8] - Total current assets decreased from ¥654.85 million to ¥497.83 million, a decline of approximately 24%[15]